. 2024 Apr 23;44(2):71–75. doi: 10.14639/0392-100X-N2745

Table I.

Summary of the most significant studies of BPD nasal spray or aerosol in patients with sinonasal disease.

Reference	Study design	Single centre or multicentric study	Patient’s population sample	Patient disease	Pharmaceutical form	Frequency daily	Daily dose (microgram/day)	Weeks of treatment	Parameters improved with treatment (parameters improved/total parameter of the score, p value)
Sonnemann et al., 2014 ¹⁰	Randomised, double blind, control, placebo study	Multicentre	50	AR	Nasal spray	2	320	2	TNSS (4/4, p < 0.001)
Weinstein et al., 2014 ¹¹	Randomised, double blind, control, placebo study	Multicentre	126	AR	Aerosol	1	320	52	QoL (1/14, p = 0.008)
Weinstein et al., 2014 ¹¹	Randomised, double blind, control, placebo study	Multicentre	126	AR	Aerosol	1	320	52	TNSS (4/4, p < 0.001)
Chong et al., 2016 ⁴	Review of randomised, double blind, control, placebol trials	Single centre	55	CRS	Nasal spray	2	400	26	PNSS (4/4, p = 0.008)
Chong et al., 2016 ⁴		Single centre	55	CRS	Nasal spray	2	400	26	Days on which patients required no rescue medication (p .009)
Rezaeian et al., 2021 ¹²	Randomised, double blind, clinical trial	Single centre	60	CRS	Nasal spray Aerosol	1	200	8	Higher percentage of days with an overall nasal blockage score on waking minor of 2 (p .013)
									Peak nasal inspiratory flow measurements (p < 0.05)
									- SNOT22 (p < 0.05)
									- Lund-Mackay score (p < 0.05)
AR: allergic rhinitis; CRS: chronic rhinosinusitis; TNSS: total nasal symptoms score (nasal congestion, sneezing, nasal itching, and rhinorrhoea); PNSS: physicians nasal symptoms score.